{"count": 10, "results": [{"_id": "32899806", "pmid": 32899806, "pmcid": "PMC7560003", "title": "Metformin: A Potential Therapeutic Tool for Rheumatologists", "journal": "Pharmaceuticals (Basel)", "authors": ["Salvatore T", "Pafundi PC", "Galiero R", "Gjeloshi K", "Masini F", "Acierno C", "Di Martino A", "Albanese G", "Alfano M", "Rinaldi L", "Sasso FC"], "date": "2020-09-04T00:00:00Z", "doi": "10.3390/ph13090234", "meta_date_publication": "2020 Sep 4", "meta_volume": "13", "meta_issue": "9", "meta_pages": "", "score": 50273.41, "text_hl": "As compared to the current drugs used in @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ treatment, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has the potential advantage of targeting multiple aspects of the disease. ", "citations": {"NLM": "Salvatore T, Pafundi PC, Galiero R, Gjeloshi K, Masini F, Acierno C, Di Martino A, Albanese G, Alfano M, Rinaldi L, Sasso FC. Metformin: A Potential Therapeutic Tool for Rheumatologists Pharmaceuticals (Basel). 2020 Sep 4;13(9):. PMID: 32899806", "BibTeX": "@article{32899806, title={Metformin: A Potential Therapeutic Tool for Rheumatologists}, author={Salvatore T and Pafundi PC and Galiero R and Gjeloshi K and Masini F and Acierno C and Di Martino A and Albanese G and Alfano M and Rinaldi L and Sasso FC}, journal={Pharmaceuticals (Basel)}, volume={13}, number={9}}"}}, {"_id": "34879473", "pmid": 34879473, "pmcid": "PMC8747910", "title": "Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease", "journal": "Korean J Intern Med", "authors": ["Kim JW", "Choe JY", "Park SH"], "date": "2022-01-01T00:00:00Z", "doi": "10.3904/kjim.2021.363", "meta_date_publication": "2022 Jan", "meta_volume": "37", "meta_issue": "1", "meta_pages": "13-26", "score": 50264.38, "text_hl": "The efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been investigated in preclinical and clinical studies on @DISEASE_Arthritis_Rheumatoid @DISEASE_MESH:D001172 @@@rheumatoid arthritis@@@, @DISEASE_Osteoarthritis @DISEASE_MESH:D010003 @@@osteoarthritis@@@, @DISEASE_Lupus_Erythematosus_Systemic @DISEASE_MESH:D008180 @@@systemic lupus erythematosus@@@, @DISEASE_Sjogren's_Syndrome @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@, @DISEASE_Scleroderma_Systemic @DISEASE_MESH:D012595 @@@scleroderma@@@, @DISEASE_Spondylitis_Ankylosing @DISEASE_MESH:D013167 @@@ankylosing spondylitis@@@, and @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@. ", "citations": {"NLM": "Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease Korean J Intern Med. 2022 Jan;37(1):13-26. PMID: 34879473", "BibTeX": "@article{34879473, title={Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease}, author={Kim JW and Choe JY and Park SH}, journal={Korean J Intern Med}, volume={37}, number={1}, pages={13-26}}"}}, {"_id": "36286721", "pmid": 36286721, "title": "[Advantages of the use of metformin in patients with impaired uric acid metabolism].", "journal": "Ter Arkh", "authors": ["Eliseev MS", "Panevin TS", "Zhelyabina OV", "Nasonov EL"], "date": "2021-05-15T00:00:00Z", "doi": "10.26442/00403660.2021.05.200795", "meta_date_publication": "2021 May 15", "meta_volume": "93", "meta_issue": "5", "meta_pages": "71520", "score": 50256.863, "text_hl": "Current data suggest that the mechanism of action of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ contributes to the development of an anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ effect, as well as a decrease in the level of @CHEMICAL_Uric_Acid @CHEMICAL_MESH:D014527 @@@uric acid@@@, and its use can be potentially useful in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hyperuricemia @DISEASE_MESH:D033461 @@@hyperuricemia@@@ and @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@.", "citations": {"NLM": "Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. [Advantages of the use of metformin in patients with impaired uric acid metabolism]. Ter Arkh. 2021 May 15;93(5):71520. PMID: 36286721", "BibTeX": "@article{36286721, title={[Advantages of the use of metformin in patients with impaired uric acid metabolism].}, author={Eliseev MS and Panevin TS and Zhelyabina OV and Nasonov EL}, journal={Ter Arkh}, volume={93}, number={5}, pages={71520}}"}}, {"_id": "38619822", "pmid": 38619822, "title": "Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.", "journal": "JAMA Intern Med", "authors": ["McCormick N", "Yokose C", "Lu N", "Wexler DJ", "Aviña-Zubieta JA", "De Vera MA", "McCoy RG", "Choi HK"], "date": "2024-04-15T00:00:00Z", "doi": "10.1001/jamainternmed.2024.0376", "meta_date_publication": "2024 Apr 15", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50256.344, "text_hl": "Sodium-Glucose Cotransporter-2 Inhibitors vs @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@Sulfonylureas@@@ for @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@Gout@@@ Prevention Among @SPECIES_9606 @@@Patients@@@ With @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@Type 2 Diabetes@@@ Receiving @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@.", "citations": {"NLM": "McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, McCoy RG, Choi HK. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin. JAMA Intern Med. 2024 Apr 15;():. PMID: 38619822", "BibTeX": "@article{38619822, title={Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.}, author={McCormick N and Yokose C and Lu N and Wexler DJ and Aviña-Zubieta JA and De Vera MA and McCoy RG and Choi HK}, journal={JAMA Intern Med}}"}}, {"_id": "32082683", "pmid": 32082683, "pmcid": "PMC7013360", "title": "A Patient with Complex Gout with an Autoinflammatory Syndrome and a Sternoclavicular Joint Arthritis as Presenting Symptoms", "journal": "Case Rep Rheumatol", "authors": ["Fedeli MM", "Vecchi M", "Rodoni Cassis P"], "date": "2020-01-31T00:00:00Z", "doi": "10.1155/2020/5026490", "meta_date_publication": "2020", "meta_volume": "2020", "meta_issue": "", "meta_pages": "5026490", "score": 50249.492, "text_hl": "The total duration of the @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ flare was 6 months.", "citations": {"NLM": "Fedeli MM, Vecchi M, Rodoni Cassis P. A Patient with Complex Gout with an Autoinflammatory Syndrome and a Sternoclavicular Joint Arthritis as Presenting Symptoms Case Rep Rheumatol. 2020;2020():5026490. PMID: 32082683", "BibTeX": "@article{32082683, title={A Patient with Complex Gout with an Autoinflammatory Syndrome and a Sternoclavicular Joint Arthritis as Presenting Symptoms}, author={Fedeli MM and Vecchi M and Rodoni Cassis P}, journal={Case Rep Rheumatol}, volume={2020}, pages={5026490}}"}}, {"_id": "35355431", "pmid": 35355431, "pmcid": "PMC9543911", "title": "Direct injection analysis of oxypurinol and metformin in wastewater by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry", "journal": "Drug Test Anal", "authors": ["Zheng Q", "Dewapriya P", "Eaglesham G", "Reeks T", "Thompson J", "Ahmed F", "Prasad P", "Thomas KV", "Mueller JF", "Thai PK"], "date": "2022-08-01T00:00:00Z", "doi": "10.1002/dta.3266", "meta_date_publication": "2022 Aug", "meta_volume": "14", "meta_issue": "8", "meta_pages": "1519-1524", "score": 50247.99, "text_hl": "The increasing global prevalence of @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ and @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ has led to a rise in the use of their respective medications, @CHEMICAL_Allopurinol @CHEMICAL_MESH:D000493 @@@allopurinol@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Zheng Q, Dewapriya P, Eaglesham G, Reeks T, Thompson J, Ahmed F, Prasad P, Thomas KV, Mueller JF, Thai PK. Direct injection analysis of oxypurinol and metformin in wastewater by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry Drug Test Anal. 2022 Aug;14(8):1519-1524. PMID: 35355431", "BibTeX": "@article{35355431, title={Direct injection analysis of oxypurinol and metformin in wastewater by hydrophilic interaction liquid chromatography coupled to tandem mass spectrometry}, author={Zheng Q and Dewapriya P and Eaglesham G and Reeks T and Thompson J and Ahmed F and Prasad P and Thomas KV and Mueller JF and Thai PK}, journal={Drug Test Anal}, volume={14}, number={8}, pages={1519-1524}}"}}, {"_id": "19705791", "pmid": 19705791, "title": "[Effect of metformin on the clinical course of gout and insulin resistance].", "journal": "Klin Med (Mosk)", "authors": ["Barskova VG", "Eliseev MS", "Kudaeva FM", "Aleksandrova EN", "Volkov AV", "Nasonova VA", "Nasonov EL"], "date": "2009-01-01T00:00:00Z", "meta_date_publication": "2009", "meta_volume": "87", "meta_issue": "7", "meta_pages": "41-6", "score": 50072.2, "text_hl": "[Effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on the clinical course of @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ and @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@].", "citations": {"NLM": "Barskova VG, Eliseev MS, Kudaeva FM, Aleksandrova EN, Volkov AV, Nasonova VA, Nasonov EL. [Effect of metformin on the clinical course of gout and insulin resistance]. Klin Med (Mosk). 2009;87(7):41-6. PMID: 19705791", "BibTeX": "@article{19705791, title={[Effect of metformin on the clinical course of gout and insulin resistance].}, author={Barskova VG and Eliseev MS and Kudaeva FM and Aleksandrova EN and Volkov AV and Nasonova VA and Nasonov EL}, journal={Klin Med (Mosk)}, volume={87}, number={7}, pages={41-6}}"}}, {"_id": "16514819", "pmid": 16514819, "title": "[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].", "journal": "Ter Arkh", "authors": ["Barskova VG", "Eliseev MS", "Nasonov EL", "Volkov AV", "Tsapina TN", "Zilov AV", "Iakunina IA", "Il'inykh EV", "Kudaeva FM"], "date": "2005-01-01T00:00:00Z", "meta_date_publication": "2005", "meta_volume": "77", "meta_issue": "12", "meta_pages": "44-9", "score": 50072.11, "text_hl": "[Use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@siofor@@@) in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ and @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@ (pilot 6-month results)].", "citations": {"NLM": "Barskova VG, Eliseev MS, Nasonov EL, Volkov AV, Tsapina TN, Zilov AV, Iakunina IA, Il'inykh EV, Kudaeva FM. [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. Ter Arkh. 2005;77(12):44-9. PMID: 16514819", "BibTeX": "@article{16514819, title={[Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)].}, author={Barskova VG and Eliseev MS and Nasonov EL and Volkov AV and Tsapina TN and Zilov AV and Iakunina IA and Il'inykh EV and Kudaeva FM}, journal={Ter Arkh}, volume={77}, number={12}, pages={44-9}}"}}, {"_id": "30814053", "pmid": 30814053, "title": "mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?", "journal": "Ann Rheum Dis", "authors": ["Vazirpanah N", "Ottria A", "van der Linden M", "Wichers CGK", "Schuiveling M", "van Lochem E", "Phipps-Green A", "Merriman T", "Zimmermann M", "Jansen M", "Radstake TRDJ", "Broen JCA"], "date": "2019-05-01T00:00:00Z", "doi": "10.1136/annrheumdis-2018-214656", "meta_date_publication": "2019 May", "meta_volume": "78", "meta_issue": "5", "meta_pages": "663-671", "score": 50057.53, "text_hl": "Consistent with this, we show that @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ who are treated with the @GENE_MTOR @GENE_2475 @@@mTOR@@@ inhibitor @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ have a lower frequency of @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ attacks. ", "citations": {"NLM": "Vazirpanah N, Ottria A, van der Linden M, Wichers CGK, Schuiveling M, van Lochem E, Phipps-Green A, Merriman T, Zimmermann M, Jansen M, Radstake TRDJ, Broen JCA. mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy? Ann Rheum Dis. 2019 May;78(5):663-671. PMID: 30814053", "BibTeX": "@article{30814053, title={mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?}, author={Vazirpanah N and Ottria A and van der Linden M and Wichers CGK and Schuiveling M and van Lochem E and Phipps-Green A and Merriman T and Zimmermann M and Jansen M and Radstake TRDJ and Broen JCA}, journal={Ann Rheum Dis}, volume={78}, number={5}, pages={663-671}}"}}, {"_id": "30782471", "pmid": 30782471, "title": "Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes.", "journal": "Can J Diabetes", "authors": ["Eskin M", "Simpson SH", "Eurich DT"], "date": "2019-07-01T00:00:00Z", "doi": "10.1016/j.jcjd.2018.12.001", "meta_date_publication": "2019 Jul", "meta_volume": "43", "meta_issue": "5", "meta_pages": "322-328", "score": 50047.402, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ users were less likely to be involved in accident-related events (adjusted hazard ratio [aHR] 0.90; 95% CI 0.85 to 0.96), were more likely to have preventive screening services (aHR 1.16; 95% CI 1.11 to 1.21), were less likely to experience other clinical events, such as @DISEASE_Asthma @DISEASE_MESH:D001249 @@@asthma@@@ and @<m>DISEASE_Gout</m> @DISEASE_MESH:D006073 @@@gout@@@ attacks (aHR 0.90; 95% CI 0.84 to 0.97), and had lower risks for all-cause mortality (aHR 0.57; 95% CI 0.51 to 0.63) compared to nonusers. ", "citations": {"NLM": "Eskin M, Simpson SH, Eurich DT. Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes. Can J Diabetes. 2019 Jul;43(5):322-328. PMID: 30782471", "BibTeX": "@article{30782471, title={Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes.}, author={Eskin M and Simpson SH and Eurich DT}, journal={Can J Diabetes}, volume={43}, number={5}, pages={322-328}}"}}]}